Bucindolol, Systolic Blood Pressure, and Outcomes in Systolic Heart Failure: A Prespecified Post Hoc Analysis of BEST

Canadian Journal of Cardiology

Volumn 28, Issue 3, 2012, Pages 354-359

  White, Michel ^a   Desai, Ravi V ^b   Guichard, Jason L ^c   Mujib, Marjan ^c   Aban, Inmaculada B ^c   Ahmed, Mustafa I ^c   Feller, Margaret A ^c   de Denus, Simon ^a   Ahmed, Ali ^c,d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b LEHIGH VALLEY HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BUCINDOLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; HAZARD RATIO; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; BLOOD PRESSURE DETERMINATION; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84860917771     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2011.07.004     Document Type: Article

References (15)

1. Desai R.V., Banach M., Ahmed M.I., et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010, 106:221-227.
2. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995, 75:1220-1223. The BEST Steering Committee.
3. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667. The BEST Investigators.
4. Rosendorff C., Black H.R., Cannon C.P., et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115:2761-2788. American Heart Association Council for High Blood Pressure Research: American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention.
5. Rothwell P.M. Treating individuals, II: subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005, 365:176-186.
6. Curtis J.P., Sokol S.I., Wang Y., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003, 42:736-742.
7. Rouleau J.L., Roecker E.B., Tendera M., et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004, 43:1423-1429.
8. Effect of metoprolol cr/xl in chronic heart failure: Metoprolol cr/xl Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007. MERIT-HF Investigators.
9. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment With Lisinopril and Survival (ATLAS) trial. Circulation 2000, 102:611-616.
10. Howlett J.G., McKelvie R.S., Costigan J., et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol 2010, 26:185-202.
11. Rouleau J.L. New and emerging drugs and device therapies for chronic heart failure in patients with systolic ventricular dysfunction. Can J Cardiol 2011, 27:296-301.
12. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol cr/xl Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF study group. JAMA 2000, 283:1295-1302.
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13. The CIBIS Investigators.
14. Bristow M.R., Larrabee P., Muller-Beckmann B., et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992, 70(suppl 1):S105-S113.
15. Hershberger R.E., Wynn J.R., Sundberg L., Bristow M.R. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990, 15:959-967.